{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:22:21Z","timestamp":1794864141895,"version":"4.9.1"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["E-26\/210.022\/2021"],"award-info":[{"award-number":["E-26\/210.022\/2021"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["E-26\/211.062\/2021"],"award-info":[{"award-number":["E-26\/211.062\/2021"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Tropica"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.actatropica.2024.107264","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T14:00:25Z","timestamp":1716732025000},"page":"107264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Tackling the challenges of human Chagas disease: A comprehensive review of treatment strategies in the chronic phase and emerging therapeutic approaches"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-3514","authenticated-orcid":false,"given":"La\u00eds Gomes","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e1tia Regina","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Policarpo Ademar Sales","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Capelini","family":"C\u00e2mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico S.","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nubia","family":"Boechat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-2901","authenticated-orcid":false,"given":"Samir Aquino","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.actatropica.2024.107264_bib0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.parint.2016.12.003","article-title":"Identification of Trypanosoma cruzi discrete typing units (DTUs) in Latin-American migrants in Barcelona (Spain)","volume":"66","author":"Abras","year":"2017","journal-title":"Parasitol. Int."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0041","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/jac\/dkx516","article-title":"What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment","volume":"73","author":"Aldasoro","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.actatropica.2024.107264_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.926699","article-title":"The repositioned drugs disulfiram\/diethyldithiocarbamate combined to benznidazole: searching for Chagas disease selective therapy, preventing toxicity and drug resistance","volume":"12","author":"Almeida-Silva","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"12","key":"10.1016\/j.actatropica.2024.107264_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052897","article-title":"New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia","volume":"11","author":"Alonso-Vega","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008912","article-title":"Prospective, historically controlled study to evaluate the efficacy and safety of a new pediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)","volume":"15","author":"Altcheh","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"5","key":"10.1016\/j.actatropica.2024.107264_bib0005","doi-asserted-by":"crossref","first-page":"e2907","DOI":"10.1371\/journal.pntd.0002907","article-title":"Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults","volume":"8","author":"Altcheh","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"9","key":"10.1016\/j.actatropica.2024.107264_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00439-20","article-title":"New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: clinical, parasitological, and serological assessment after three years of follow-up","volume":"64","author":"\u00c1lvarez","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0007","first-page":"721","article-title":"Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types","volume":"63","author":"Andrade","year":"1985","journal-title":"Bull. World Health Organ."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4269\/ajtmh.1998.59.133","article-title":"Treatment of chronic Chagas' disease with itraconazole and allopurinol","volume":"59","author":"Apt","year":"1998","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1179\/000349803125002751","article-title":"Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up","volume":"97","author":"Apt","year":"2003","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"9","key":"10.1016\/j.actatropica.2024.107264_bib0010","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/jac\/dkt135","article-title":"Treatment of Chagas' disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up","volume":"68","author":"Apt","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.actatropica.2024.107264_bib0011","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/45.6.819","article-title":"A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease","volume":"45","author":"Ara\u00fajo","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.actatropica.2024.107264_bib0013","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1128\/AAC.02754-13","article-title":"Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease","volume":"58","author":"Bahia","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.actatropica.2024.107264_bib0014","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1371\/journal.pntd.0001870","article-title":"Fexinidazole: a potential new drug candidate for chagas disease","volume":"6","author":"Bahia","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"12","key":"10.1016\/j.actatropica.2024.107264_bib0015","article-title":"Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in Trypanosoma cruzi-infected cardiac cells","volume":"25","author":"Barbosa","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01852-21","article-title":"Experimental combination therapy with amiodarone and low-dose benznidazole in a mouse model of Trypanosoma cruzi acute infection","volume":"10","author":"Barbosa","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.actatropica.2024.107264_bib0017","unstructured":"Bayer A.G. LAMPIT prescribing information, January 2022. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Lampit_PI.pdf. Accessed 19 January 2023."},{"issue":"3","key":"10.1016\/j.actatropica.2024.107264_bib0018","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/jm050691f","article-title":"Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole","volume":"49","author":"Benaim","year":"2006","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1473-3099(23)00629-1","article-title":"Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial","volume":"24","author":"Bosch-Nicolau","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1590\/S0074-02761993000100023","article-title":"An experimental and clinical assay with ketoconazole in the treatment of Chagas disease","volume":"88","author":"Brener","year":"1993","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0022","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/infdis\/jit420","article-title":"New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice","volume":"209","author":"Bustamante","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12978-020-00972-1","article-title":"Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol","volume":"17","author":"Cafferata","year":"2020","journal-title":"Reprod. Health"},{"issue":"Suppl I","key":"10.1016\/j.actatropica.2024.107264_bib0024","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1590\/S0074-02761999000700064","article-title":"Criteria of CD cure","volume":"94","author":"Can\u00e7ado","year":"1999","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1590\/S0036-46652002000100006","article-title":"Long term evaluation of etiological treatment of chagas disease with benznidazole","volume":"44","author":"Can\u00e7ado","year":"2002","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"issue":"9710","key":"10.1016\/j.actatropica.2024.107264_bib0028","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)61422-7","article-title":"Socioeconomic aspects of neglected tropical diseases","volume":"375","author":"Conteh","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.actatropica.2024.107264_bib0029","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1590\/S0037-86821997000200009","volume":"30","author":"Coura","year":"1997","journal-title":"Rev. Soc. Bras. Med. Trop."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","article-title":"A critical review on Chagas disease chemotherapy","volume":"97","author":"Coura","year":"2002","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.actatropica.2024.107264_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2022.108266","article-title":"Benznidazole, itraconazole, and their combination for the treatment of chronic experimental Chagas disease in dogs","volume":"238","author":"Cunha","year":"2022","journal-title":"Exp. Parasitol."},{"issue":"9039","key":"10.1016\/j.actatropica.2024.107264_bib0032","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(96)04128-1","article-title":"Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection","volume":"348","author":"de Andrade","year":"1996","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0033","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00436-006-0172-5","article-title":"Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection","volume":"99","author":"de Castro","year":"2006","journal-title":"Parasitol. Res."},{"issue":"3","key":"10.1016\/j.actatropica.2024.107264_bib0034","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1371\/journal.ppat.0020024","article-title":"Ancestral genomes, sex, and the population structure of Trypanosoma cruzi","volume":"2","author":"de Freitas","year":"2006","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0035","doi-asserted-by":"crossref","first-page":"11200","DOI":"10.1038\/s41598-021-90719-0","article-title":"Insights of antiparasitic activity of sodium diethyldithiocarbamate against different strains of Trypanosoma cruzi","volume":"11","author":"de Freitas","year":"2021","journal-title":"Sci. Rep."},{"issue":"10422","key":"10.1016\/j.actatropica.2024.107264_bib0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01787-7","article-title":"Chagas disease","volume":"403","author":"de Sousa","year":"2024","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.actatropica.2024.107264_bib0039","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/0037-8682-0505-2016","article-title":"2nd Brazilian consensus on chagas disease","volume":"49","author":"Dias","year":"2015","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.actatropica.2024.107264_bib0040","unstructured":"DNDi, 2023. https:\/\/dndi.org\/wp-content\/uploads\/2023\/07\/DNDi-RD-Portfolio-June-2023.pdf."},{"key":"10.1016\/j.actatropica.2024.107264_bib0042","article-title":"Efficacy of the benznidazole + posaconazole combination therapy in parasitemia reduction: an experimental murine model of acute Chagas","volume":"53","author":"Echeverr\u00eda","year":"2019","journal-title":"Rev. Soc. Bras. Med. Trop."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0037-86822007000100001","article-title":"Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution","volume":"40","author":"Fabbro","year":"2007","journal-title":"Rev. Soc. Bras. Med. Trop."},{"issue":"2","key":"10.1016\/j.actatropica.2024.107264_bib0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1590\/S0036-46652000000200007","article-title":"Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients","volume":"42","author":"Fabbro-Suasn\u00e1bar","year":"2000","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"issue":"5","key":"10.1016\/j.actatropica.2024.107264_bib0046","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02021-21","article-title":"Effectiveness of nifurtimox in the treatment of Chagas disease: a long-term retrospective cohort study in children and adults","volume":"66","author":"Falk","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.actatropica.2024.107264_bib0047","unstructured":"FDA Approved Drugs, 2020. LAMPIT (Nifurtimox) label. Availableat: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=213464. Accessed May 01, 2024."},{"key":"10.1016\/j.actatropica.2024.107264_bib0048","unstructured":"FDA News Release, 2017. FDA approves first U.S. treatment for Chagas disease.FDA. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-us-treatment-chagas-disease. Accessed december 16, 2022."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0049","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/AAC.01170-06","article-title":"The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole","volume":"51","author":"Ferraz","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1590\/S0037-86821990000400005","article-title":"Tratamento da forma indeterminada da doen\u00e7a de Chagas com nifurtimox e benzonidazol [Treatment of the undetermined form of Chagas disease with nifortimox and benzonidazole]","volume":"23","author":"Ferreira","year":"1990","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.actatropica.2024.107264_bib0051","unstructured":"Fiocruz, 2022 Fiocruz registra primeiro kit para diagn\u00f3stico molecular de Chagas. Dispon\u00edvel em: https:\/\/portal.fiocruz.br\/noticia\/fiocruz-registra-primeiro-kit-para-diagnostico-molecular-de-chagas. Acesso em 25 de janeiro de 2024."},{"issue":"3","key":"10.1016\/j.actatropica.2024.107264_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004508","article-title":"Evaluation of parasiticide treatment with benznidazol in the electrocardiographic, clinical, and serological evolution of chagas disease","volume":"10","author":"Fragata-Filho","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2024.107264_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112020","article-title":"Advances in the treatment of Chagas disease: promising new drugs, plants and targets","volume":"142","author":"Garc\u00eda-Huertas","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.actatropica.2024.107264_bib0055","first-page":"513","article-title":"Antiprotozoan and antibacterial activity of 2-nitroimidazole derivatives","volume":"7","author":"Grunberg","year":"1967","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0057","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0058","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benznidazole by trypanosomal type i nitroreductases results in glyoxal formation","volume":"56","author":"Hall","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"31","key":"10.1016\/j.actatropica.2024.107264_bib0059","article-title":"Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: a long-term follow up study","volume":"23","author":"Hasslocher-Moreno","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/01.CIR.67.1.45","article-title":"Side effects of long-term amiodarone therapy","volume":"67","author":"Harris","year":"1983","journal-title":"Circulation"},{"issue":"40","key":"10.1016\/j.actatropica.2024.107264_bib0061","article-title":"Effects of Selenium treatment on cardiac function in Chagas heart disease: results from the STCC randomized Trial","volume":"28","author":"Holanda","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.actatropica.2024.107264_bib0062","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17512433.2018.1509704","article-title":"Clinical and pharmacological profile of benznidazole for treatment of Chagas disease","volume":"11","author":"Kratz","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"7619","key":"10.1016\/j.actatropica.2024.107264_bib0063","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.actatropica.2024.107264_bib0064","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bcp.14700","article-title":"Review of pharmacological options for the treatment of Chagas disease","volume":"88","author":"Lascano","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3\u20134","key":"10.1016\/j.actatropica.2024.107264_bib0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4269\/ajtmh.2000.63.111","article-title":"Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives","volume":"63","author":"Lauria-Pires","year":"2000","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0066","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1473-3099(13)70002-1","article-title":"Global economic burden of Chagas disease: a computational simulation model","volume":"13","author":"Lee","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.actatropica.2024.107264_bib0067","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.actatropica.2015.07.015","article-title":"Genetic diversity of Trypanosoma cruzi in bats, and multilocus phylogenetic and phylogeographical analyses supporting Tcbat as an independent DTU (discrete typing unit)","volume":"151","author":"Lima","year":"2015","journal-title":"Acta Trop."},{"key":"10.1016\/j.actatropica.2024.107264_bib0068","series-title":"American Trypanosomiasis","first-page":"489","article-title":"Implications of Trypanosoma cruzi intraspecific diversity in the pathogenesis of chagas disease","author":"Macedo","year":"2010"},{"issue":"8","key":"10.1016\/j.actatropica.2024.107264_bib0069","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009697","article-title":"The Chagas disease study landscape: a systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform","volume":"15","author":"Maguire","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2024.107264_bib130","doi-asserted-by":"crossref","unstructured":"Martins T.A.F., de Figueiredo Diniz L., Mazzeti A.L., da Silva do Nascimento \u00c1.F., Caldas S, Caldas IS, de Andrade IM, et al., 2015. Benznidazole\/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease. PLoS One. 10(6):e0128707. doi:10.1371\/journal.pone.0128707. PMID: 26076455; PMCID: PMC4468053.","DOI":"10.1371\/journal.pone.0128707"},{"key":"10.1016\/j.actatropica.2024.107264_bib0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/JEP.S267378","article-title":"Review on experimental treatment strategies against Trypanosoma cruzi","volume":"13","author":"Mazzeti","year":"2021","journal-title":"J. Exp. Pharmacol."},{"issue":"6","key":"10.1016\/j.actatropica.2024.107264_bib0071","doi-asserted-by":"crossref","first-page":"e02264","DOI":"10.1128\/AAC.02264-18","article-title":"Synergic effect of allopurinol in combination with nitro-heterocyclic compounds against Trypanosoma cruzi","volume":"63","author":"Mazzeti","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"36","key":"10.1016\/j.actatropica.2024.107264_bib0072","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.2174\/092986732636191202125919","article-title":"Chagas disease treatment: from new therapeutic targets to drug discovery and repositioning","volume":"26","author":"Miranda","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"20","key":"10.1016\/j.actatropica.2024.107264_bib0073","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0074","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/AAC.44.1.150-155.2000","article-title":"Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts","volume":"44","author":"Molina","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0075","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13063-020-4226-2","article-title":"Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial","volume":"21","author":"Molina-Morant","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.actatropica.2024.107264_bib131","doi-asserted-by":"crossref","unstructured":"Moraes C.B., Giardini M.A., Kim H., Franco C.H., Araujo-Junior A.M., Schenkman S., et al., 2014. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep. 4:4703. doi:10.1038\/srep04703. PMID: 24736467; PMCID: PMC4004771.","DOI":"10.1038\/srep04703"},{"key":"10.1016\/j.actatropica.2024.107264_bib0076","first-page":"1236","article-title":"Valida\u00e7\u00e3o do Kit NAT Chagas IVD para Detec\u00e7\u00e3o e Quantifica\u00e7\u00e3o de Trypanosoma cruzi em Amostras de Sangue de Pacientes com Doen\u00e7a de Chagas","volume":"13","author":"Moreira","year":"2023","journal-title":"Vida"},{"issue":"14","key":"10.1016\/j.actatropica.2024.107264_bib0077","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic chagas' cardiomyopathy","volume":"373","author":"Morillo","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.actatropica.2024.107264_bib0078","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and posaconazole in eliminating parasites in asymptomatic T. Cruzi carriers: the STOP-CHAGAS trial","volume":"69","author":"Morillo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.actatropica.2024.107264_bib0079","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007668","article-title":"Longitudinal follow up of serological response in children treated for Chagas disease","volume":"13","author":"Moscatelli","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"9","key":"10.1016\/j.actatropica.2024.107264_bib0081","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1128\/AAC.00227-13","article-title":"Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods","volume":"57","author":"Mu\u00f1oz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.actatropica.2024.107264_bib0082","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0166-6851(98)00037-1","article-title":"Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox","volume":"93","author":"Murta","year":"1998","journal-title":"Mol. Biochem. Parasitol."},{"issue":"6","key":"10.1016\/j.actatropica.2024.107264_bib0083","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4269\/ajtmh.15-0256","article-title":"Safety profile of nifurtimox and treatment interruption for chronic chagas disease in Colombian adults","volume":"93","author":"Olivera","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0084","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijantimicag.2010.03.006","article-title":"A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease","volume":"36","author":"Olivieri","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"10.1016\/j.actatropica.2024.107264_bib0053","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11897-022-00568-9","article-title":"Chronic chagas disease-the potential role of reinfections in cardiomyopathy pathogenesis","volume":"19","author":"Olivo Freites","year":"2022","journal-title":"Curr. Heart Fail. Rep."},{"issue":"10","key":"10.1016\/j.actatropica.2024.107264_bib0085","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41564-022-01211-y","article-title":"Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates","volume":"7","author":"Padilla","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.actatropica.2024.107264_bib0086","unstructured":"Pan American Health Organization. Guidelines for the diagnosis and treatment of Chagas disease; 2019. https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/49653\/9789275120439_eng.pdf."},{"issue":"n. 6","key":"10.1016\/j.actatropica.2024.107264_bib0087","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"v. 30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"issue":"10115","key":"10.1016\/j.actatropica.2024.107264_bib0088","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"P\u00e9rez-Molina","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.actatropica.2024.107264_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00651-5","article-title":"Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial","author":"Pinazo","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"10.1016\/j.actatropica.2024.107264_bib0090","first-page":"1611","article-title":"Single-dose pharmacokinetics of the trypanosomicide benznidazole in man","volume":"29","author":"Raaflaub","year":"1979","journal-title":"Arzneimittelforschung"},{"issue":"12","key":"10.1016\/j.actatropica.2024.107264_bib0091","first-page":"2192","article-title":"Multiple-dose kinetics of the trypanosomicide benznidazole in man","volume":"30","author":"Raaflaub","year":"1980","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0093","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4269\/ajtmh.2007.76.58","article-title":"Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease","volume":"76","author":"Rassi","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2024.107264_bib0094","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpddr.2019.11.004","article-title":"Current trends in the pharmacological management of Chagas disease","volume":"12","author":"Ribeiro","year":"2020","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"issue":"5","key":"10.1016\/j.actatropica.2024.107264_bib0095","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4269\/ajtmh.16-0761","article-title":"Experimental and clinical treatment of Chagas disease: a review","volume":"97","author":"Sales Junior","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"12","key":"10.1016\/j.actatropica.2024.107264_bib0096","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4330\/wjc.v13.i12.654","article-title":"Chagas heart disease: an overview of diagnosis, manifestations, treatment, and care","volume":"13","author":"Saraiva","year":"2021","journal-title":"World J. Cardiol."},{"issue":"n. 7","key":"10.1016\/j.actatropica.2024.107264_bib0097","first-page":"1","article-title":"Disulfiram repurposing in the combined chemotherapy of Chagas Disease. A protocol for phase I\/II clinical trial","volume":"v. 2","author":"Saraiva","year":"2021","journal-title":"Med. Case Rep. Study Prot."},{"issue":"3","key":"10.1016\/j.actatropica.2024.107264_bib0099","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jac\/dkg338","article-title":"Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction","volume":"52","author":"Schijman","year":"2003","journal-title":"J. Antimicrob. Chemother"},{"issue":"2","key":"10.1016\/j.actatropica.2024.107264_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.echo.2018.09.006","article-title":"Effects of trypanocidal treatment on echocardiographic parameters in chagas cardiomyopathy and prognostic value of wall motion score index: a BENEFIT trial echocardiographic substudy","volume":"32","author":"Schmidt","year":"2019","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0101","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1128\/AAC.01215-08","article-title":"Amiodarone destabilizes intracellular Ca2+ homeostasis and biosynthesis of sterols in Leishmania mexicana","volume":"53","author":"Serrano-Mart\u00edn","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0104","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4269\/ajtmh.1998.59.526","article-title":"Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease","volume":"59","author":"Sosa Estani","year":"1998","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"2","key":"10.1016\/j.actatropica.2024.107264_bib0105","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz012","article-title":"Progression of baseline electrocardiogram abnormalities in Chagas Patients undergoing antitrypanosomal treatment","volume":"6","author":"Soverow","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.actatropica.2024.107264_bib0106","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1590\/S0037-86822004000500001","article-title":"Estudo longitudinal e quimioterapia espec\u00edfica em crian\u00e7as, com doen\u00e7a de Chagas cr\u00f4nica, residentes em \u00e1rea de baixa endemicidade da Rep\u00fablica Argentina","volume":"37","author":"Streiger","year":"2004","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.actatropica.2024.107264_bib0107","first-page":"25","article-title":"Diagnosis and clinical management of chagas disease: an increasing challenge in non-endemic areas","volume":"13","author":"Su\u00e1rez","year":"2022","journal-title":"Res. Rep. Trop. Med."},{"issue":"6","key":"10.1016\/j.actatropica.2024.107264_bib0108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008311","article-title":"Quantification of parasite burden of Trypanosoma cruzi and identification of Discrete Typing Units (DTUs) in blood samples of Latin American immigrants residing in Barcelona, Spain","volume":"14","author":"Tavares de Oliveira","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"8","key":"10.1016\/j.actatropica.2024.107264_bib0109","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1473-3099(20)30844-6","article-title":"New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial","volume":"21","author":"Torrico","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"5","key":"10.1016\/j.actatropica.2024.107264_bib0111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002844","article-title":"Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics","volume":"8","author":"Trochine","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.actatropica.2024.107264_bib0112","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/S0074-02762009000900041","article-title":"Ergosterol biosynthesis and drug development for Chagas disease","volume":"104","author":"Urbina","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0113","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(17)30535-2","article-title":"The long road towards a safe and effective treatment of chronic Chagas disease","volume":"18","author":"Urbina","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/j.actatropica.2024.107264_bib0114","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/AAC.42.7.1771","article-title":"Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies","volume":"42","author":"Urbina","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0924-8579(02)00273-X","article-title":"In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease","volume":"21","author":"Urbina","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"2","key":"10.1016\/j.actatropica.2024.107264_bib0117","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17460441.2020.1681394","article-title":"Why hasn't there been more progress in new Chagas disease drug discovery?","volume":"15","author":"Vermelho","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"issue":"8","key":"10.1016\/j.actatropica.2024.107264_bib0118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221100","article-title":"Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox","volume":"14","author":"Vergara","year":"2019","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0119","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13063-019-3423-3","article-title":"Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial","volume":"20","author":"Villar","year":"2019","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.actatropica.2024.107264_bib0120","doi-asserted-by":"crossref","first-page":"724","DOI":"10.7326\/0003-4819-144-10-200605160-00006","article-title":"Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial","volume":"144","author":"Viotti","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.actatropica.2024.107264_bib0121","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0002-8703(94)90521-5","article-title":"Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up","volume":"127","author":"Viotti","year":"1994","journal-title":"Am. Heart J."},{"issue":"10","key":"10.1016\/j.actatropica.2024.107264_bib0122","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009801","article-title":"Serological response to nifurtimox in adult patients with chronic Chagas disease: an observational comparative study in Argentina","volume":"15","author":"Vizcaya","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"2","key":"10.1016\/j.actatropica.2024.107264_bib0123","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1534\/genetics.104.038745","article-title":"Two hybridization events define the population structure of Trypanosoma cruzi","volume":"171","author":"Westenberger","year":"2005","journal-title":"Genetics"},{"key":"10.1016\/j.actatropica.2024.107264_bib0124","unstructured":"WHO, 2023. Chagas disease (also known as American trypanosomiasis), 2022. Dispon\u00edvel em: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-(american-trypanosomiasis). Acesso em: 25 jan.2023."},{"issue":"4","key":"10.1016\/j.actatropica.2024.107264_bib0125","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.3314\/mmj.16-00006","article-title":"Potential of ravuconazole and its prodrugs as the new oral therapeutics for onychomycosis","volume":"57","author":"Yamaguchi","year":"2016","journal-title":"Med. Mycol. J."},{"issue":"6","key":"10.1016\/j.actatropica.2024.107264_bib0126","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1371\/journal.pntd.0001049","article-title":"Multilocus sequence typing (MLST) for lineage assignment and high resolution diversity studies in Trypanosoma cruzi","volume":"5","author":"Yeo","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"7","key":"10.1016\/j.actatropica.2024.107264_bib0127","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1371\/journal.pntd.0000488","article-title":"Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas Disease in Honduras, Guatemala, and Bolivia: 10-year experience of m\u00e9decins sans fronti\u00e8res","volume":"3","author":"Yun","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"7","key":"10.1016\/j.actatropica.2024.107264_bib132","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1590\/S0074-02762009000700021","article-title":"A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI","volume":"104","author":"Zingales","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"12","key":"10.1016\/j.actatropica.2024.107264_bib0128","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3390\/life13122339","article-title":"Fifteen years after the definition of Trypanosoma cruzi DTUs: what have we learned?","volume":"13","author":"Zingales","year":"2023","journal-title":"Life"},{"issue":"38","key":"10.1016\/j.actatropica.2024.107264_bib0129","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.2174\/1381612827666210216152654","article-title":"Chagas disease chemotherapy: what do we know so far?","volume":"27","author":"Zuma","year":"2021","journal-title":"Curr. Pharm. Des."}],"container-title":["Acta Tropica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X24001463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X24001463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T15:18:00Z","timestamp":1718464680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001706X24001463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":118,"alternative-id":["S0001706X24001463"],"URL":"https:\/\/doi.org\/10.1016\/j.actatropica.2024.107264","relation":{},"ISSN":["0001-706X"],"issn-type":[{"value":"0001-706X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tackling the challenges of human Chagas disease: A comprehensive review of treatment strategies in the chronic phase and emerging therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Acta Tropica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actatropica.2024.107264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107264"}}